Universiteit
Leiden
The Netherlands

PKPD relationships and dose rationale in analgesic drug development : towards the prediction of target engagement

Taneja, A.

Citation
Taneja, A. (2013, November 20). *PKPD relationships and dose rationale in analgesic drug development : towards the prediction of target engagement*. Retrieved from https://hdl.handle.net/1887/22300

Version:	Corrected Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/22300

Note: To cite this publication please use the final published version (if applicable).

Cover Page

Universiteit Leiden

The handle http://hdl.handle.net/1887/22300 holds various files of this Leiden University dissertation.

Author: Taneja, Amit
Title: PKPD relationships and dose rationale in analgesic drug development : towards the prediction of target engagement
Issue Date: 2013-11-20

PKPD RELATIONSHIPS AND DOSE RATIONALE IN ANALGESIC DRUG DEVELOPMENT-TOWARDS THE PREDICTION OF TARGET ENGAGEMENT

Amit Taneja

COLOFON

The research presented in this thesis was supported by a PhD research fellowship from the Top Institute Pharma, a tripartite consortium involving industry, academia and the Netherlands government and was performed at the Division of Pharmacology of the Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Cover photo:	6 blind men and the elephant, depiction by Neha Bahuguna, Bangalore. Based on an idea from wordinfo.info, John Robertson.
Layout:	Nikki Vermeulen, Ridderprint BV, Ridderkerk, the Netherlands
Production:	Ridderprint BV, Ridderkerk, the Netherlands
ISBN:	978-90-5335-738-5

© Amit Taneja, 2013

amitvtaneja@yahoo.co.in

All rights reserved. No part of this publication may be reproduced, or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval without prior written permission from the author, or, when appropriate the publisher holding the copyright of the published articles.

PKPD RELATIONSHIPS AND DOSE RATIONALE IN ANALGESIC DRUG DEVELOPMENT-TOWARDS THE PREDICTION OF TARGET ENGAGEMENT

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. Carel Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 20 november 2013
klokke 16.15 uur

door

Amit Taneja
geboren te Namkum, Ranchi, India
in 1970

PROMOTIECOMMISSIE

Promotor:	Prof. dr. M. Danhof
Co-promotor:	Dr. O.E. Della Pasqua
Promotiecommissie:	Dr. I Troconiz (Universidad de Navarra, Spanje)
	Dr. A. Hooker (Uppsala Universitet, Zweden)
	Prof. Dr. P.H. van der Graaf
	Prof. Dr. A. Dahan
	Prof. Dr. J. Van Gerven
	Prof. Dr. T. Hankemeier
	Prof. Dr. A.P. IJzerman

Take risks in your life, If u win you can lead, if you lose, you can guide

-Swami Vivekananda

To Aanchal and Avnay

TABLE OF CONTENTS

SECTION I	GENERAL INTRODUCTION - TRANSLATIONAL PHARMACOLOGY OF DRUG EFFECTS IN CHRONIC PAIN	9
Chapter 1	Challenges in translational drug research in neuropathic and inflammatory pain: Towards a new paradigm	11
Chapter 2	Translation of drug effects from experimental models of neuropathic pain and analgesia to humans	39
Chapter 3	PKPD relationships and dose rationale in analgesic drug development: Scope and intent of investigations	67
SECTION II	MODEL-BASED ANALYSIS OF BEHAVIOURAL PAIN RESPONSE	79
Chapter 4	Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain	81
Chapter 5	Optimised protocol design for the screening of analgesic compounds in neuropathic pain	101
Chapter 6	Semi- mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain	121
SECTION III	LOST IN TRANSLATION-FROM BIOMARKER TO CLINICAL ENDPOINT	151
Chapter 7	Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from an *ex-vivo* model of inflammatory pain	153
Chapter 8	Pharmacokinetic-pharmacodynamic modelling of the core set of outcome measures (ACRn) in rheumatoid arthritis	177
Chapter 9	Exploratory analysis of the correlation between pain relief and target engagement in rheumatoid arthritis	203

SECTION IV CONCLUSIONS AND PERSPECTIVES 223

Chapter 10 Analgesic drug development at the crossroads: where do we go from here? Thesis summary, conclusions and perspectives 225

Chapter 11 Nederlandse samenvatting (Summary in dutch) 243

APPENDICES Acknowledgements/Dankwoord 259

List of Publications 265